XPO1 and breast carcinoma: To test this hypothesis, we treated breast carcinoma MCF7 cells with CRM1 inhibitor leptomycin B (LMB) and monitored the nucleo-cytoplasmic translocation of SMURF2 in these cells using western blot analysis.